Sei Investments Co. Sells 43,166 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Sei Investments Co. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 30.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 98,338 shares of the company's stock after selling 43,166 shares during the period. Sei Investments Co. owned about 0.32% of Medpace worth $32,671,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of MEDP. Pallas Capital Advisors LLC raised its position in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Barclays PLC increased its stake in shares of Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after buying an additional 8,275 shares during the period. Sanctuary Advisors LLC raised its position in shares of Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after acquiring an additional 844 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Medpace by 10.0% in the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company's stock worth $14,722,000 after acquiring an additional 4,023 shares during the period. Finally, SYM FINANCIAL Corp bought a new stake in Medpace in the fourth quarter valued at approximately $320,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on MEDP shares. Leerink Partners initiated coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Finally, Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $376.30.

Remove Ads

Medpace Trading Down 1.3 %

Medpace stock traded down $4.25 during midday trading on Friday, reaching $312.36. The stock had a trading volume of 343,137 shares, compared to its average volume of 298,736. The company has a fifty day moving average price of $335.90 and a two-hundred day moving average price of $339.15. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The company has a market capitalization of $9.52 billion, a P/E ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.